These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29424243)

  • 1. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
    Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
    J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL; Hirte H; Konner JA; Lim PC; Prasad-Hayes M; Monk BJ; Pautier P; Wang J; Berkenblit A; Vergote I; Birrer MJ
    Ann Oncol; 2021 Jun; 32(6):757-765. PubMed ID: 33667670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
    Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
    Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
    Fowler M
    Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D; Cristea M
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirvetuximab Soravtansine: First Approval.
    Heo YA
    Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
    Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.